What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Brian O'Sullivan mostly deals with Surgery, Radiation therapy, Internal medicine, Cancer and Soft tissue sarcoma.
His Surgery study frequently draws parallels with other fields, such as Univariate analysis.
His Radiation therapy research is multidisciplinary, incorporating elements of Carcinoma, Chemotherapy, Nuclear medicine and Head and neck.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Oncology.
His Cancer research is multidisciplinary, incorporating perspectives in Stage, Mucosal melanoma and Pathology.
He studied Soft tissue sarcoma and Neoadjuvant therapy that intersect with Randomization.
His most cited work include:
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial (979 citations)
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis (828 citations)
- Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health (773 citations)
What are the main themes of his work throughout his whole career to date?
Brian O'Sullivan focuses on Internal medicine, Radiation therapy, Surgery, Oncology and Cancer.
Brian O'Sullivan regularly ties together related areas like Gastroenterology in his Internal medicine studies.
His research in Radiation therapy intersects with topics in Nuclear medicine, Carcinoma, Chemotherapy and Clinical trial.
The study of Surgery is intertwined with the study of Sarcoma in a number of ways.
His Oncology research focuses on subjects like Nasopharyngeal carcinoma, which are linked to Cancer research.
As a part of the same scientific study, he usually deals with the Cancer, concentrating on Disease and frequently concerns with Intensive care medicine.
He most often published in these fields:
- Internal medicine (40.12%)
- Radiation therapy (39.53%)
- Surgery (34.97%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (40.12%)
- Oncology (30.41%)
- Radiation therapy (39.53%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Radiation therapy, Cancer and Head and neck cancer.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
The concepts of his Oncology study are interwoven with issues in Head and neck squamous-cell carcinoma, Clinical trial and Quality of life.
His Radiation therapy study combines topics from a wide range of disciplines, such as Cohort and Hazard ratio.
His work in Cancer covers topics such as Disease which are related to areas like Intensive care medicine.
All of his Surgery and Soft tissue sarcoma and Retrospective cohort study investigations are sub-components of the entire Surgery study.
Between 2016 and 2021, his most popular works were:
- Head and Neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual (599 citations)
- Overview of the 8th Edition TNM Classification for Head and Neck Cancer (164 citations)
- Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial (149 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His main research concerns Internal medicine, Oncology, Radiation therapy, Cancer and Hazard ratio.
In his study, Chemotherapy is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine.
The concepts of his Oncology study are interwoven with issues in Head and neck squamous-cell carcinoma, Clinical trial, Disease and MEDLINE.
His study on Radiation therapy is covered under Surgery.
His studies in Cancer integrate themes in fields like Carcinoma, Lymph node and Human papillomavirus.
His Hazard ratio research is multidisciplinary, incorporating perspectives in Nuclear medicine, Cohort and Performance status.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
